Phosphate buffered saline, pH 7.4 containing 0.01% sodium azide
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
1 mg/ml (Please refer to the vial label for the specific concentration.)
Synthetic peptide - KLH conjugated
Immunogen affinity purified.
Peptide immunogen affinity column
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Vasoactive Intestinal Peptide Receptor 1,Hvr1,Ii,Pacap-R-2,Pacap-R2,Rdc1,V1Rg,Vapc1,Vip-R-1,Vipr,Virg,Vpac1,Vpac1R,Vpcap1R,Vipr1
Vasoactive Intestinal Polypeptide Receptor 1 (VIPR1) is a member of the Vasoactive Intestinal Polypeptide subfamily. Vasoactive intestinal peptide (VIP) plays multiple roles in the nervous, endocrine, and immune systems as a neurotransmitter, a hormone, and a cytokine. VIPR1, a receptor for VIP, has been shown to expressed widely in normal tissues and is the predominant receptor subtype for VIP in cancers. VIP and its receptors, VIPR1 and VIPR2, are highly expressed in the immune system and modulate diverse T cell functions. Recently VIP-R1 has been shown to be a novel and potent facilitator of HIV-1 infection. Two isoforms are produced by alternative splicing. VIPR1 expression has been documented widely in normal and cancerous tissues, including adipose, adrenal, bladder, blood, brain, breast, colon, ganglion, GI tract, heart, kidney, liver, lung, lymph node, ovary, pancreas, placenta, prostate, skin, small intestine, spinal cord, spleen, stomach, testis, thymus, thyroid, and vessel. ESTs have been isolated from a diverse set of normal and cancerous tissues.